All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Eltanexor granted fast track designation by the FDA and orphan medicinal product designation by the EC

Aug 4, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in MDS.

On July 20, 2022, eltanexor, a novel oral selective inhibitor of nuclear export, was granted fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory intermediate-, high-, or very high-risk myelodysplastic syndromes (MDS).1 The European Commission (EC) also designated eltanexor as an orphan medicinal product for the treatment of MDS in the European Union.1

Eltanexor (KPT-8602) is a novel selective inhibitor of nuclear export compound that binds with, and inhibits, the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins in the cell nucleus. This is believed to lead to the selective induction of apoptosis in cancer cells, leaving normal cells largely unaffected. The FDA previously granted eltanexor orphan drug designation in January 2022.1

A phase I/II open-label study is currently ongoing investigating eltanexor in patients with relapsed/refractory MDS. Eltanexor has been previously covered by the MDS Hub.

  1. Karyopharm Therapeutics. Karyopharm granted regulatory designations for eltanexor for the treatment of myelodysplastic syndromes. https://investors.karyopharm.com/2022-07-20-Karyopharm-Granted-Regulatory-Designations-for-Eltanexor-for-the-Treatment-of-Myelodysplastic-Syndromes. Published Jul 20, 2022. Accessed Aug 2, 2022.

More about...